tradingkey.logo

Johnson & Johnson rises on planned $1 billion investment in Pennslyvania

ReutersFeb 18, 2026 6:39 PM

Shares of Johnson & Johnson JNJ.N rise 0.3% to $244.40 after the company said it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania

JNJ is on track to snap two straight sessions of losses

The investment is part of its larger plans announced last year to scale up U.S. manufacturing amid President Donald Trump's tariff threats

In March, the company announced a plan to invest more than $55 billion through early 2029 to build manufacturing facilities and the research infrastructure in the U.S.

Other major drugmakers, including Eli Lilly LLY.N and AstraZeneca AZN.L, have also committed billions of dollars in investments to scale up their U.S. footprint in response to Trump's tariff threats

Among 28 analysts covering JNJ, avg rating is "buy" and the median PT is $237, per LSEG data

JNJ up 18% YTD vs S&P 500 health care index .SPXHC, which is up 1.3%

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI